Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism

Bayer106 enrolled

Overview

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Study Type

OBSERVATIONAL

Enrollment

106

Conditions

Atrial Fibrillation

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

15 mg OD or 20 mg OD

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients ≥ 18 years old with a confirmed diagnosis of non-valvular atrial fibrillation * Patients must in addition present with at least one of following risk factors: * prior stroke, TIA (transient ischemic attack) or non-CNS (central nervous system) systemic embolism * left ventricular ejection fraction of \< 40% * symptomatic heart failure, New York Heart Association class 2 or higher * age ≥75 years * age ≥65 years in combination with either diabetes, coronary disease or arterial hypertension Exclusion Criteria: * Patients who do not fulfil the Belgian reimbursement criteria

Locations (1)

Unnamed facility

Many Locations, Belgium